These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18260166)

  • 1. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity.
    Seriolo B; Ferrone C; Cutolo M
    J Rheumatol; 2008 Feb; 35(2):355-7. PubMed ID: 18260166
    [No Abstract]   [Full Text] [Related]  

  • 2. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
    J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 6. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
    Eberhardt K; Sandqvist G; Geborek P
    Scand J Rheumatol; 2008; 37(2):109-12. PubMed ID: 18415767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased adiponectin levels in women with rheumatoid arthritis after etanercept treatment.
    Lewicki M; Kotyla P; Kucharz E
    J Rheumatol; 2009 Jun; 36(6):1346-7; author reply 1347. PubMed ID: 19509093
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 9. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
    Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
    Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
    [No Abstract]   [Full Text] [Related]  

  • 10. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
    Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
    J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
    Rozin AP; Braun-Moscovici Y; Balbir-Gurman A
    Ann Pharmacother; 2008 Dec; 42(12):1912-3. PubMed ID: 19033477
    [No Abstract]   [Full Text] [Related]  

  • 14. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al.
    van der Laken CJ; Lems WF; van Soesbergen RM; van der Sande JJ; Dijkmans BA
    Arthritis Rheum; 2003 Jan; 48(1):269-70. PubMed ID: 12528130
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
    Kaliterna DM
    Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
    Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
    Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.